+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06517212

Study of Tirzepatide with Standard Hormone Therapy in Adults With High-Risk, Node-Positive, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer and Excess Weight

Led by Baylor Research Institute · Updated on 2026-02-12

48

Participants Needed

1

Research Sites

69 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying whether weight loss caused by tirzepatide affects survival outcomes in patients with high-risk early breast cancer who are overweight or have obesity. The focus is on patients with hormone receptor-positive, HER2-negative, and node-positive breast cancer. The study aims to see if this weight loss can clear circulating tumor DNA ctDNA and prevent the development of metastatic disease over two years. This is a Phase 2 clinical trial conducted by the Baylor Research Institute. Participants who test positive for ctDNA will receive tirzepatide through weekly injections, starting at 2.5 mg and increasing monthly to 15 mg over six months. Treatment may continue for up to two years if there is no evidence of metastatic disease and if tirzepatide is well tolerated. Patients will be monitored monthly for the first six months and every two months afterward. Before treatment, ctDNA testing occurs every three months for up to three years or until ctDNA is detected, followed by imaging to confirm no visible metastases. During the study, patients will have regular clinic visits for safety and tolerability checks, weight monitoring, and blood tests to track ctDNA changes. The main outcomes measured are ctDNA clearance and distant disease-free survival over two years. Secondary measures include treatment-related adverse events and weight loss. Participants need to be accessible for treatment and follow-up for the study duration, which may last up to several years depending on ctDNA status and treatment length.

CONDITIONS

Brief Title

Tirzepatide Weight Loss for MRD+ Early Breast Cancer

Research Team

C

CORC Solid Tumor

P

Page E Blas, MA

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here